Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)
Savara (SVRA) reported Net Income towards Common Stockholders of -$37.3 million for Q1 2026, down 39.96% year-over-year from -$62.1 million in Q1 2025, and down 15.66% quarter-over-quarter from -$32.2 million in Q4 2025.
Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$37.3 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$37.3 million, down 39.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129.5 million (down 26.73% YoY), and the FY2025 annual result was -$118.8 million, down 23.94% from the prior year.
- Net Income towards Common Stockholders eased to -$37.3 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$8.3 million in Q1 2022 and troughed at -$37.3 million in Q1 2026.
- A 5-year average of -$20.3 million and a median of -$20.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders advanced 18.76% in 2022, then sank 94.38% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.3 million in 2022, then slumped by 56.3% to -$16.1 million in 2023, then sank by 80.41% to -$29.0 million in 2024, then decreased by 10.99% to -$32.2 million in 2025, then retreated by 15.66% to -$37.3 million in 2026.
- Business Quant data shows SVRA's Net Income towards Common Stockholders at -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -37.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.28 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -30.40 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.04 Mn |
| Sep 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -22.24 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.10 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.39 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -10.55 Mn |
| Jun 30, 2021 | -10.94 Mn |